Alvarez & Marsal Announces 2025 Managing Director Promotions
16.1.2025 17:36:00 CET | Business Wire | Press release
Leading global professional services firm Alvarez & Marsal (A&M) has announced the promotion of 80 professionals, across Brazil, Canada, France, Germany, India, Italy, Spain, Sweden, United Arab Emirates, United Kingdom, and the United States, to the position of Managing Director.
Tony Alvarez II and Bryan Marsal, A&M’s Co-Founders, stated, “All of our newly promoted Managing Directors embody the talent and leadership necessary to deliver exceptional results that create value for A&M’s clients. Their contributions to the growth of our firm and the clients we serve cannot be understated. From around the world and across our many lines of service, they exemplify A&M’s unwavering commitment to integrity, quality and objectivity, and are essential to the firm’s continued success and expansion.”
- Russell Hunt, Houston
- Jack Kobus, Detroit
- Long Nguyen, Washington, D.C.
- Luis De Lencquesaing, New York
- Christopher Disa, New York
- Phani Mogalapu,Houston
Corporate Performance Improvement
- Kindra Bradshaw, Washington, D.C.
- Clark Caperton, Houston
- Rodrigo Carrillo, Houston
- Jeffrey Cass, Houston
- Trey Huffman, Atlanta
- Rob Koczo,Dallas
- Haley Leyendecker, Denver
- Andrew Monaco, Dallas
- Dan Phillips, Atlanta
- Brenden Phillips-Garrett, Los Angeles
- Eduardo Areilza, Madrid
- Massimo Franzese, London
- Tom Howitt, Abu Dhabi
- Hardeep Sandhu, London
- Florian Seehauser, Munich
- Jonas Strasdas, Munich
Private Equity Performance Improvement
- Colleen McCaughan, London
- Nick Mountfield, London
- Daniela Torresin, Milan
- Dario Bortot,London
- John Costoudes, Dubai
- Elizaveta Malashenko, Houston
Global Disputes and Investigations
- Jon Ahern, Denver
- Brad Koehler, New York
- John Bettley-Smith, London
- Daniella Divito,New York
- Emily Edwards, Atlanta
- Orion Ganase,London
- Alon Kritzman, New York
- Bruce Meyer, San Francisco
- Michael Noreman, Morristown
- Axel Ortjohann, Frankfurt
- Rob Piechota, Atlanta
- Chris Prout, London
Global Transaction Advisory Group
- Mike Baxter,Toronto
- Erminio Caporale, Chicago
- Kevin Cunha,San Francisco
- Ryan Donovan,Boston
- Vivian Leemans,Düsseldorf
- Kate Lowry,New York
- Ryan Macke, Chicago
- Callum Moore, Stockholm
- Gaurav Patel,Toronto
- Alex Rankin, Dubai
- Simon Regad,Paris
- Paul Spencer, London
- Michael Surr,New York
- Austin Wanland, Los Angeles
- Sujith Jain, Bangalore
Infrastructure & Capital Projects
- Felipe Bergson, Rio de Janeiro
- Bryan Müller, Belo Horizonte
- Alexandre Aguieiras, Rio de Janeiro
- Janice Garay, São Paulo
- Guilherme Kam, São Paulo
- Patrick Lopes, São Paulo
- Eduardo Teixeira, São Paulo
North American Commercial Restructuring
- Dwight Hingtgen,Chicago
- Landon Kenworthy,Dallas
- Paul Kinealy,Chicago
- Kumanan Ramanathan, New York
- Mauricio Rivera,San Francisco
- John Walsh,Houston
Private Equity Performance Improvement
- Alexander Galitsky,Chicago
- Vincent Juron,Charlotte
- Jason Kahn,Philadelphia
- Jeff Liddle, Houston
- Ahmed Suria,Philadelphia
- Ben Taylor,Atlanta
- Shiwali Tenner,Chicago
- Hameer Vaid,New York
- Christopher Baglio, Chicago
- Tracey Esposito, New York
- Roger Wilcock, London
About Alvarez & Marsal
Founded in 1983, Alvarez & Marsal is a leading global professional services firm. Renowned for its leadership, action and results, Alvarez & Marsal provides advisory, business performance improvement and turnaround management services, delivering practical solutions to address clients' unique challenges. With a world-wide network of experienced operators, world-class consultants, former regulators and industry authorities, Alvarez & Marsal helps corporates, boards, private equity firms, law firms and government agencies drive transformation, mitigate risk and unlock value at every stage of growth.
To learn more, visit: AlvarezandMarsal.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250114027719/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom